A GLOBAL LEADER IN CANNABINOID DERIVED THERAPEUTICS FOR COMPANION ANIMALS
CannPal Animal Therapeutics is a global leader in the development of innovative, cannabinoid-derived therapeutic products to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and more natural way.
Presently, the Company is developing products containing CBD, THC and other active ingredients for registration and commercialisation as veterinary medicines and nutraceuticals in the areas of pain, inflammation, mood and dermatological skin conditions.
CannPal is a subsidiary of AusCann Group Holdings (ASX:AC8) an Australian, Publicly listed company focused on the development and commercialisation of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. You can learn more about AusCann Group Holdings here
Investors and shareholders
Pet Owners and veterinarians
Innovative and naturally derived therapeutic products
CannPal Animal Therapeutics Limited Ltd is an animal health company developing innovative and naturally derived plant-based therapeutic products for pets targeting the endocannabinoid system that owners can trust are both safe and scientifically validated.
The company has a research focus on cannabinoids, the active pharmaceutical ingredients extracted from the cannabis plant, to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and animal health markets by developing innovative therapeutics that can influence the endocannabinoid system with full regulatory approval for veterinary distribution.
A unique investment opportunity in a growing market
CannPal Animal Therapeutics Limited (“CannPal”) is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals. The company is a 100% Wholly Owned Subsidiary of AusCann Group Holdings, a publicly listed Pharmaceutical Company on the Australian Stock Exchange (ASX), trading under the ASX ticker “AC8”. CannPal was founded to research, develop and commercialise, regulatory approved medicines derived from the medical cannabis plant to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.